Teva Pharmaceutical Industries Revenue 2012-2026 | TEVA
Teva Pharmaceutical Industries annual/quarterly revenue history and growth rate from 2012 to 2026. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
- Teva Pharmaceutical Industries revenue for the quarter ending March 31, 2026 was $3.982B, a 2.34% increase year-over-year.
- Teva Pharmaceutical Industries revenue for the twelve months ending March 31, 2026 was $17.349B, a 4.41% increase year-over-year.
- Teva Pharmaceutical Industries annual revenue for 2025 was $17.258B, a 4.32% increase from 2024.
- Teva Pharmaceutical Industries annual revenue for 2024 was $16.544B, a 4.4% increase from 2023.
- Teva Pharmaceutical Industries annual revenue for 2023 was $15.846B, a 6.17% increase from 2022.
|
Teva Pharmaceutical Industries Annual Revenue (Millions of US $) |
|
|---|---|
| 2025 | $17,258 |
| 2024 | $16,544 |
| 2023 | $15,846 |
| 2022 | $14,925 |
| 2021 | $15,878 |
| 2020 | $16,659 |
| 2019 | $16,887 |
| 2018 | $18,271 |
| 2017 | $22,385 |
| 2016 | $21,903 |
| 2015 | $19,652 |
| 2014 | $20,272 |
| 2013 | $20,314 |
| 2012 | $20,317 |
| 2011 | $18,312 |
|
Teva Pharmaceutical Industries Quarterly Revenue (Millions of US $) |
|
|---|---|
| 2026-03-31 | $3,982 |
| 2025-12-31 | $4,711 |
| 2025-09-30 | $4,480 |
| 2025-06-30 | $4,176 |
| 2025-03-31 | $3,891 |
| 2024-12-31 | $4,229 |
| 2024-09-30 | $4,332 |
| 2024-06-30 | $4,164 |
| 2024-03-31 | $3,819 |
| 2023-12-31 | $4,457 |
| 2023-09-30 | $3,850 |
| 2023-06-30 | $3,878 |
| 2023-03-31 | $3,661 |
| 2022-12-31 | $3,883 |
| 2022-09-30 | $3,595 |
| 2022-06-30 | $3,786 |
| 2022-03-31 | $3,661 |
| 2021-12-31 | $4,099 |
| 2021-09-30 | $3,887 |
| 2021-06-30 | $3,910 |
| 2021-03-31 | $3,982 |
| 2020-12-31 | $4,454 |
| 2020-09-30 | $3,978 |
| 2020-06-30 | $3,870 |
| 2020-03-31 | $4,357 |
| 2019-12-31 | $4,468 |
| 2019-09-30 | $4,093 |
| 2019-06-30 | $4,177 |
| 2019-03-31 | $4,149 |
| 2018-12-31 | $3,976 |
| 2018-09-30 | $4,529 |
| 2018-06-30 | $4,701 |
| 2018-03-31 | $5,065 |
| 2017-12-31 | $5,398 |
| 2017-09-30 | $5,617 |
| 2017-06-30 | $5,720 |
| 2017-03-31 | $5,650 |
| 2016-12-31 | $6,492 |
| 2016-09-30 | $5,563 |
| 2016-06-30 | $5,038 |
| 2016-03-31 | $4,810 |
| 2015-12-31 | $4,881 |
| 2015-09-30 | $4,823 |
| 2015-06-30 | $4,966 |
| 2015-03-31 | $4,982 |
| 2014-12-31 | $5,168 |
| 2014-09-30 | $5,058 |
| 2014-06-30 | $5,045 |
| 2014-03-31 | $5,001 |
| 2013-12-31 | $5,430 |
| 2013-09-30 | $5,059 |
| 2013-06-30 | $4,924 |
| 2013-03-31 | $4,901 |
| 2012-12-31 | $5,249 |
| 2012-09-30 | $4,972 |
| 2012-06-30 | $4,994 |
| 2012-03-31 | $5,102 |
| 2011-12-31 | $5,676 |
| 2011-09-30 | $4,344 |
| 2011-06-30 | $4,212 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $35.437B | $17.258B |
| Teva Pharmaceutical Industries Limited is a global pharmaceutical company that develops, manufactures, and markets both branded and generic drugs, as well as active pharmaceutical ingredients in North America, Europe, Latin America, India, and Israel. Teva's generic product portfolio includes tablets, capsules, liquids, ointments, creams, liquids, injectables, and inhalants. The company's branded products include Copaxone, Austedo, respiratory products like ProAir and Qvar and Ajovy. Teva operates through three segments, North America, Europe and International Markets, each of which includes generics, specialty and over-the-counter products. Teva acquired Allergan's generics business Actavis Generics. The company also acquired Allergan's Anda Inc. Teva acquired Auspex Pharmaceuticals and Barr. Teva has strengthened its position in Europe through its acquisition of Germany's second largest generics producer, ratiopharm. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma (BBIO) | United States | $14.460B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $11.109B | 17.29 |
| Aspen Pharmacare (APNHY) | South Africa | $3.708B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.918B | 22.33 |
| Bausch Health Cos (BHC) | Canada | $2.086B | 1.50 |
| Taysha Gene Therapies (TSHA) | United States | $1.290B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $0.924B | 7.28 |
| Personalis (PSNL) | United States | $0.630B | 0.00 |
| Assembly Biosciences (ASMB) | United States | $0.451B | 0.00 |
| Sol-Gel Technologies (SLGL) | Israel | $0.210B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.052B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |